-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J75vYwt0yoG1K3x7Bfm4Q4EVWQAb/gorT9ZyGT/+20v1H6mXZFY931ssh9XpAXrn wvTZPX9zRqriweAV6GzMhA== 0000929624-01-000227.txt : 20010214 0000929624-01-000227.hdr.sgml : 20010214 ACCESSION NUMBER: 0000929624-01-000227 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010213 GROUP MEMBERS: ANSELM LEUNG ("LEUNG") GROUP MEMBERS: BIOASIA INVESTMENTS LLC GROUP MEMBERS: BIOASIA MANAGEMENT, LLC ("BAM") GROUP MEMBERS: BIOTECHNOLOGY DEVELOPMENT FUND II, L.P. ("BDF II") GROUP MEMBERS: BIOTECHNOLOGY DEVELOPMENT FUND III, L.P. ("BDF III") GROUP MEMBERS: BIOTECHNOLOGY DEVELOPMENT FUND, L.P. ("BDF") GROUP MEMBERS: EDGAR ENGLEMAN ("ENGLEMAN") GROUP MEMBERS: FRANK KUNG ("KUNG") SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: INTERMUNE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943296648 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-60673 FILM NUMBER: 1537512 BUSINESS ADDRESS: STREET 1: 1710 GILBRETH RD STREET 2: SUITE 301 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 6504938333 MAIL ADDRESS: STREET 1: 3924 WEST BAYSHORE BLVD CITY: PALO ALTO STATE: CA ZIP: 94303 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOASIA INVESTMENTS LLC CENTRAL INDEX KEY: 0001103307 STANDARD INDUSTRIAL CLASSIFICATION: [] STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 575 HIGH STREET SUITE 201 CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 6506880821 MAIL ADDRESS: STREET 1: 575 HIGH STREET STE 201 CITY: PALO ALTO STATE: CA ZIP: 94301 SC 13G 1 0001.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ______)* Intermune Pharmaceuticals, Inc. - ------------------------------------------------------------------------------ (Name of Issuer) Common Stock, Par Value $0.001 Per Share - ------------------------------------------------------------------------------- (Title of Class of Securities) 458858100 - -------------------------------------------------------------------------------- (CUSIP Number) Check the following box if a fee is being paid with this statement [_]. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7). *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 14 Pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Biotechnology Development Fund, L.P. ("BDF") 94-3258409 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. Delaware - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 1,035,801 shares, except that BioAsia Investments, LLC ("BioAsia"), the general partner of BDF, and Frank Kung ("Kung"), Anselm Leung ("Leung") and Edgar Engleman ("Engleman"), members of BioAsia, may be deemed to have shared power to vote these shares. SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. 450,412 shares. The 450,412 shares are owned directly Biotechnology Development Fund III, L.P. ("BDF" III"). BDF may be deemed to have shared power to vote through a 24.8% limited partnership interest in BDF III. OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7. REPORTING 1,035,801 shares, except that BioAsia, the general partner of BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared power to dispose of these shares. PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 450,412 shares. The 450,412 shares are owned directly by BDF III. BDF may be deemed to have shared power to dispose of these shares through a 24.8% limited partnership interest in BDF III. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,486,213 shares - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11. 6.22% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. PN - ------------------------------------------------------------------------------ Page 2 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Biotechnology Development Fund II, L.P. ("BDF II") 77-0512031 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. Delaware - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 58,140 shares, except that BAM, the general partner of BDF II, and Kung, Leung and Engleman, members of BAM, may be deemed to have shared power to vote these shares. SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 0 ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7. REPORTING 58,140 shares, except that BAM, the general partner of BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared power to dispose of these shares. PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 0 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 58,140 shares. - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11. 0.24% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. PN - ------------------------------------------------------------------------------ Page 3 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Biotechnology Development Fund III, L.P. ("BDF III") 77-0474834 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. Delaware - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 450,412 shares, except that BDF, BioAsia, the general partner of BDF III and BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared power to vote these shares. SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 0 ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7. REPORTING 450,412 shares, except that BDF, BioAsia, the general partner of BDF III and BDF, and Kung, Leung and Engleman, members of BioAsia, may be deemed to have shared power to dispose of these shares. PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 0 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 450,412 shares. - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11. 1.89% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. PN - ------------------------------------------------------------------------------ Page 4 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON BioAsia Investments, LLC ("BioAsia") 94-3258407 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. California - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 1,486,213 shares, 1,035,801 of which are directly owned by BDF and 450,412 of which are owned directly EACH by BDF III. As the general partner of BDF and BDF III, BioAsia may be deemed to have shared power to vote REPORTING these shares. ----------------------------------------------------------- PERSON SOLE DISPOSITIVE POWER 7. WITH 0 ----------------------------------------------------------- SHARED DISPOSITIVE POWER 8. 1,486,213 shares, 1,035,801 of which are directly owned by BDF and 450,412 of which are owned directly by BDF III. As the general partner of BDF and BDF III, BioAsia may be deemed to have shared power to dispose of these shares. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,486,213 shares. - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11. 6.22% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. OO - ------------------------------------------------------------------------------ Page 5 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON BioAsia Management, LLC ("BAM") 77-0547105 - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. California - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 58,140 shares which are directly owned by BDF II. As the general partner of BDF II, BAM may be deemed to have shared power to vote these shares. ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7. REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 58,140 shares which are directly owned by BDF II. As the general partner of BDF II, BAM may be deemed to have shared power to dispose of these shares. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 58,140 shares. - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 11. 0.24% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. OO - ------------------------------------------------------------------------------ Page 6 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1. S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Frank Kung ("Kung") ###-##-#### - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. United States - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 2,736 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 1,544,535 shares, 1,035,801 of which are directly owned by BDF, 58,140 of which are owned directly by EACH BDF II, and 450,412 of which are owned directly by BDF III. Kung is member of BioAsia and BAM and may be deemed to have shared power to vote these shares. REPORTING ----------------------------------------------------------- SOLE DISPOSITIVE POWER PERSON 7. WITH 2,736 shares ----------------------------------------------------------- SHARED DISPOSITIVE POWER 8. 1,544,535 shares, 1,035,801 of which are directly owned by BDF, 58,140 of which are owned directly by BDF II, and 450,412 of which are owned directly by BDF III. Kung is member of BioAsia and BAM and may be deemed to have shared power to dispose of these shares. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,547,089 shares. - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 11. 6.47% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. IN - ------------------------------------------------------------------------------ Page 7 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1. S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Anselm Leung ("Leung") ###-##-#### - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. United States - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 5,000 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 1,544,353 shares, 1,035,801 of which are directly owned by BDF, 58,140 of which are owned directly by BDF II, and 450,412 of which are owned directly by BDF III. Leung is a member of BioAsia and BAM and may be deemed to have shared power to vote these shares. ------------------------------------------------------------ EACH SOLE DISPOSITIVE POWER 7. REPORTING 5,000 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 1,544,353 shares, 1,035,801 of which are directly owned by BDF, 58,140 of which are owned directly by BDF II, and 450,412 of which are owned directly by BDF III, Leung is a member of BioAsia and BAM and may be deemed to have shared power to dispose of these shares. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,549,353 shares. - ------------------------------------------------------------------------------ CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 11. 6.48% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. IN - ------------------------------------------------------------------------------ Page 8 of 14 pages - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1. S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Edgar Engleman ("Engleman") ###-##-#### - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2. (a) [_] (b) [X] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. United States - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 122,236 shares. The 122,236 shares include options to purchase 20,000 shares. SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 1,544,353 shares, 1,035,801 of which are directly owned by BDF, 58,140 of which are owned directly by BDF II, and 450,412 of which are owned directly by BDF III. Engleman is a member of BioAsia and BAM and may be deemed to have shared power to vote these shares. ------------------------------------------------------------ EACH SOLE DISPOSITIVE POWER 7. REPORTING 122,236 shares. The 122,236 shares include options to purchase 20,000 shares. PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 1,544,353 shares,1.035,801 of which are directly owned by BDF, 58,140 of which are owned directly by BDF II, and 450,412 of which are owned directly by BDF III, Engleman is a member of BioAsia and BAM and may be deemed to have shared power to dispose of these shares. - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,666,589 shares. - ------------------------------------------------------------------------------ CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 10. [_] N.A. - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 11. 6.98% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 12. IN - ------------------------------------------------------------------------------ Page 9 of 14 pages Item 1. (a) Name of Issuer: Intermune Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices: 1710 Gilbreth Road, Suite 301 Burlingame, California 94010 Item 2. (a) Name of Person(s) Filing: BioAsia Investments, LLC, a California limited liability company ("BioAsia"), BioAsia Management, LLC, a California limited liability company ("BAM"), Biotechnology Development Fund, L.P., a Delaware limited partnership ("BDF"), Biotechnology Development Fund II, L.P., a Delaware limited partnership ("BDF II"), Biotechnology Development Fund III, L.P., a Delaware limited partnership ("BDF III"), Frank Kung ("Kung"), Anselm Leung ("Leung"), and Edgar Engleman ("Engleman") hereby make this single joint filing statement on Schedule 13G with respect to certain shares of common stock of Intermune Pharmaceuticals, Inc. ("Issuer")) as follows. BDF, BDF II, BDF III, BioAsia, BAM, Kung, Leung and Engleman are each sometimes referred to as a Reporting Person and, collectively, referred to as the Reporting Persons. BioAsia is the general partner of BDF and BDF III, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by BDF or beneficially owned by BDF through a 24.8% limited partnership interest in BDF III. BAM is the general partner of BDF II. Kung, Leung, and Engleman are members of BioAsia and BAM and may be deemed to have indirect beneficial ownership of the shares of the Issuer directly and indirectly owned by BDF and directly owned by BDF III and BDF II. BioAsia and BAM hereby disclaim beneficial ownership of shares of the Issuer directly owned by BDF, BDF II and BDF III except to the extent of any indirect pecuniary interest therein. Keung, Leung, and Engleman hereby disclaim beneficial ownership of the shares held by BDF, BDF II and BDF III except to the extent of any respective indirect pecuniary interest therein. Engleman is a member of the board of directors of the Issuer. (b) Address of Principal Business Office or, if none, Residence: The address of each Reporting Person is: 575 High Street, Suite 201, Palo Alto, California 94301 (c) Citizenship: BDF, BDF II and BDF III are Delaware limited partnerships. BioAsia and BAM are California limited liability companies. Kung, Leung and Engleman are United States citizens. (d) Title of Class of Securities: Common Stock, $0.001 par value. (e) CUSIP Number: 458858100 Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b), check whether the person filing is a: N.A. Page 10 of 14 pages Item 4. Ownership Ownership as of February 9, 2001 is incorporated by reference to items (5)-(9) and (11) of the cover page for each Reporting Person. In December 2000, BDF sold 169,400 shares of Common Stock in three separate Rule 144 sales. No other transactions have occurred since December 2000. Item 5. Ownership of Five Percent or Less of a Class N.A. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Under certain circumstances set forth in the limited partnership agreements of BDF, BDF II and BDF III and the limited liability company operating agreements of BioAsia and BAM, the general and limited partners of BDF, BDF II and BDF III and the members of BioAsia and BAM each may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or member, as applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company N.A. Item 8. Identification and Classification of Members of the Group N.A. Item 9. Notice of Dissolution of Group N.A. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Page 11 of 14 pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 9, 2001 ---------------- Biotechnology Development Fund, L.P., By: BioAsia Investments, LLC, General Partner By: /s/Frank Kung ------------------------------ Frank Kung, Member Biotechnology Development Fund II, L.P. By: BioAsia Management, LLC, General Partner By: /s/Frank Kung ------------------ Frank Kung, Member Biotechnology Development Fund III, L.P. By: BioAsia Investments, LLC, General Partner By: /s/Frank Kung ------------------ Frank Kung, Member BioAsia Investments, LLC By: /s/ Frank Kung ------------------ Frank Kung, Member BioAsia Management, LLC By: /s/ Frank Kung ------------------ Frank Kung, Member /s/ Frank Kung --------------------------- Frank Kung /s/ Anselm Leung ---------------------------- Anselm Leung /s/ Edgar Engleman ------------------------------ Edgar Engleman ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 100) Page 12 of 14 pages EXHIBIT INDEX Found on Sequentially Exhibit Numbered Page ------------- Exhibit A: Agreement of Joint Filing Page 14 Page 13 of 14 pages EX-99 2 0002.txt EXHIBIT 99.1(A) EXHIBIT A Agreement of Joint Filing The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of Intermune Pharmaceuticals, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Dated: February 9, 2001. Biotechnology Development Fund, L.P., By: BioAsia Investments, LLC, General Partner By: /s/Frank Kung ------------------------------ Frank Kung, Member Biotechnology Development Fund II, L.P. By: BioAsia Management, LLC, General Partner By: /s/Frank Kung ------------------------------ Frank Kung, Member Biotechnology Development Fund III, L.P. By: BioAsia Investments, LLC, General Partner By: /s/Frank Kung ------------------------------ Frank Kung, Member BioAsia Investments, LLC By: /s/Frank Kung ------------------------------------ Frank Kung, Member BioAsia Management, LLC By: /s/Frank Kung ------------------------------------ Frank Kung, Member /s/Frank Kung ----------------------------------- Frank Kung /s/Anselm Leung ------------------------------------ Anselm Leung /s/Edgar Engleman ------------------------------------ Edgar Engleman Page 14 of 14 pages -----END PRIVACY-ENHANCED MESSAGE-----